Dynavax Technologies (NASDAQ:DVAX)‘s stock had its “buy” rating restated by stock analysts at Cowen in a report released on Wednesday. They presently have a $30.00 target price on the biopharmaceutical company’s stock. Cowen’s price objective would indicate a potential upside of 72.91% from the stock’s previous close.
Several other analysts have also issued reports on DVAX. Cantor Fitzgerald boosted their price target on Dynavax Technologies from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Thursday, November 9th. ValuEngine lowered Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Friday, December 1st. BidaskClub lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Zacks Investment Research lowered Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. Finally, JPMorgan Chase & Co. lowered Dynavax Technologies from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $31.00 to $25.00 in a research note on Wednesday, February 14th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. Dynavax Technologies has an average rating of “Hold” and an average target price of $24.83.
Shares of Dynavax Technologies (DVAX) opened at $17.35 on Wednesday. Dynavax Technologies has a fifty-two week low of $3.90 and a fifty-two week high of $24.45. The stock has a market capitalization of $1,050.00, a PE ratio of -8.85 and a beta of 1.08.
In other news, VP David Louis Johnson sold 3,092 shares of the company’s stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $18.60, for a total value of $57,511.20. Following the completion of the transaction, the vice president now owns 7,780 shares of the company’s stock, valued at $144,708. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Robert Coffman sold 7,500 shares of the company’s stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $18.90, for a total value of $141,750.00. The disclosure for this sale can be found here. Corporate insiders own 2.90% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in DVAX. Lord Abbett & CO. LLC bought a new position in shares of Dynavax Technologies in the second quarter worth about $7,777,000. Clearbridge LLC bought a new position in Dynavax Technologies during the fourth quarter valued at approximately $10,335,000. Senvest Management LLC boosted its stake in Dynavax Technologies by 29.3% during the fourth quarter. Senvest Management LLC now owns 1,541,588 shares of the biopharmaceutical company’s stock valued at $28,828,000 after buying an additional 349,288 shares during the last quarter. Bain Capital Public Equity Management LLC bought a new position in Dynavax Technologies during the fourth quarter valued at approximately $4,657,000. Finally, EAM Investors LLC bought a new position in Dynavax Technologies during the third quarter valued at approximately $5,116,000. 65.81% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Dynavax Technologies (DVAX) Rating Reiterated by Cowen” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/23/dynavax-technologies-dvax-rating-reiterated-by-cowen.html.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.